Examining Molecular Testing in Metastatic Urothelial Cancer: Present and Future
A key opinion leader offers a comprehensive overview of the present landscape of molecular testing in metastatic urothelial cancer, elaborating on how advancements in molecular testing have shaped his clinical practice and expressing optimism for their future incorporation into the National Comprehensive Cancer Network (NCCN) guidelines.
EP: 1.Overview a 73-Year-Old Man with Metastatic Urothelial Carcinoma Case
EP: 2.Metastatic Urothelial Carcinoma: Optimizing Care Through Multidisciplinary Teamwork
EP: 3.Examining Molecular Testing in Metastatic Urothelial Cancer: Present and Future
EP: 4.Expert Insights: Biomarker Evaluation and Timing in Management of Patients with mUC
EP: 5.Navigating First-Line Treatment Choices for Metastatic Urothelial Carcinoma
EP: 6.Navigating Later-Line Therapies for Progressive Urothelial Cancer
EP: 7.Managing a Novel Therapeutic Option for mUC Treatment
EP: 8.Challenges, Unmet Needs, and the Future of Advanced Urothelial Carcinoma Management
- Please provide an overview of the current state and evolution of molecular testing in metastatic urothelial cancer.
- How has molecular testing and targeted agents changed your practice in treating mUC?
- Discuss NCCN recommendations and if/how your practice aligns.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
